How Radioactive Iodine Treatment Affects the Retina
- PMID: 38152097
- PMCID: PMC10751155
- DOI: 10.1055/s-0043-1774419
How Radioactive Iodine Treatment Affects the Retina
Abstract
Objective The aim of this study was to quantitatively assess the macular and retinal nerve fiber layer thicknesses in patients with hyperthyroidism and thyroid cancer undergoing radioactive iodine (RAI) therapy. Study Design This prospective study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Bagcilar Training and Research Hospital Clinical Research Ethics Committee. Written informed consent was obtained from the patients following a detailed explanation of the study objectives and protocol. Patient selection was randomized. Patients scheduled for RAI treatment in the Nuclear Medicine Clinic were referred to the ophthalmology clinic, respectively. Patients without additional ocular pathology were included in the study. Methods All patients had received RAI therapy using Iodine-131 for hyperthyroidism or thyroid cancer. A complete ophthalmological examination and measurement of macular and retinal nerve fiber layer thickness using optical coherence tomography were performed on all patients before and at the first and sixth months and in first year after RAI treatment. The results were prospectively evaluated. Results The study included 80 eyes of 40 patients. The hyperthyroid group was group 1, and the thyroid cancer group was group 2. There were 25 patients in group 1 and 15 patients in group 2. The mean age was 43.76 ± 11.85 years (range: 22-65 years) in group 1 and 39.87 ± 9.13 years (range: 30-58 years) in group 2. There was no significant difference between the two groups regarding age and sex ( p > 0.05). In both groups, no significant difference was found in the macular thickness and retinal nerve fiber layer thicknesses values obtained in both eyes before and after the RAI treatment. Conclusion As a result of our study, we observed that RAI intake did not harm the retinal layer.
Keywords: Macula; hyperthyroidism; nerve fiber layer; radioactive iodine; thyroid cancer.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).
Conflict of interest statement
Conflict of Interest None declared.
References
-
- Silberstein E B, Alavi A, Balon H R et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. 131. J Nucl Med. 2012;53(10):1633–1651. - PubMed
-
- American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer . Cooper D S, Doherty G M, Haugen B R et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. - PubMed
-
- European Thyroid Cancer Taskforce . Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J W, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(06):787–803. - PubMed
-
- Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. 131. Thyroid. 2009;19(12):1381–1391. - PubMed
-
- Haugen B R. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab. 2004;89(08):3665–3667. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
